Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
Aliya A KhanHajar AbuAlrobIman M'HiriDalal S AliKarel DandurandHosay SaidHisham AlkassemYasser HakamiIsmail HweijaSalman IqbalMihai RomanovschiShehryar MehmoodHeather ZariffehGordon GuyattQuazi IbrahimRomina Brignardello-PetersenHamza I SyedPublished in: Endocrine (2023)
We observed stable BMD following a switch from denosumab 60 mg every 6 months to 30 mg every 6 months in this prospective observational study conducted in postmenopausal women at a moderate fracture risk.